We had the parallel discussion on the board about SNY and what they would do in the case of a single generic Lovenox entrant and we see how that has played out so far. But, in the case of multiple entrants, isn't it expected that a company would end up launching an authorized generic? Wouldn't those principles apply to the PFE/FoB Enbrel situation as well?
Market Data 
Markets 
AI
